NCT02974504已完成4 期
A Multicenter, Randomized, Double-blind, Active-contrelled, Parallel-group, Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin After Oral Administration in Patiend With Type 2 Diabetes
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 207
- 试验地点
- 1
- 主要终点
- HbA1c
研究概览
简要总结
A multi-center, randomized, double-blind, active-controlled, parallel group, phase IV clinical trial to investigate the effect on blood glucose of evogliptin after oral administration in patients with type 2 diabetes
详细描述
- Evogliptin 5mg Group: Administration with Evogliptin 5mg for 0-24 weeks.
- Liniagliptin 5mg Group: Administration with linagliptin 5mg for 0-12 weeks, and with Evogliptin 5mg for 13-24 weeks
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects with 7.0%≤HbA1c≤10.0% at screening
- •Subjects untreated with oral hypoglycemic agents within 8 weeks prior to screening
- •Subjects with 20kg/m2≤BMI≤40kg/m2 at screening
排除标准
- •Subjects with fasting plasma glucose≥270mg/dL at screening
- •Patients with type 1 diabetes mellitus, secondary diabetes mellitus or gestational diabetes mellitus
- •Subjects with history of myocardial infarction, cerebral infarction within 24 weeks prior to screening
- •Subjects with ALT and AST 3 times or higher than upper normal range
研究组 & 干预措施
evogliptin
Experimental
evogliptin 5mg qd
干预措施: evogliptin (Drug)
linagliptin
Active Comparator
linagliptin 5mg qd
干预措施: Linagliptin (Drug)
结局指标
主要结局
HbA1c
时间窗: Change from baseline at 12 week
unit: %
次要结局
- fasting plasma glucose(Change from baseline at 12 week)
- HbA1c response rate(Change from baseline at 12 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver DiseasesType2 DiabetesNon-Alcoholic Fatty Liver DiseaseNCT03910361Dong-A ST Co., Ltd.51
已完成
4 期
Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic ControlDiabetes MellitusNCT05743907Dong-A ST Co., Ltd.231
已完成
4 期
A Study to Evaluate the Efficacy and of Stillen Tab. and to Demonstrate the Non-inferiority of Stillen Tab.Acute GastritisChronic GastritisNCT01817556Dong-A ST Co., Ltd.258
已完成
3 期
A Study to Evaluate the Efficacy and Safety of AD-203Acute GastritisChronic GastritisNCT04066530Addpharma Inc.475
已完成
3 期
A Study To Evaluate CKD-701 and Lucentis® in Patients With Neovascular(Wet) Age Related Macular DegenerationNeovascular(Wet) Age Related Macular DegenerationNCT04857177Chong Kun Dang Pharmaceutical312